CytoReason

Our focus here at CytoReason is on improving probability of success in phase 2 clinical trials. This matters not just to phama companies, but also to patients suffering from a range of debilitating illnesses. Success in phase 2 trials can help us identify treatments with fewer side effects, better quality of life outcomes, and improved disease control compared to Standard of Care drugs. Thanks Parker Moss from Exscientia for driving home this point at our recent CytoSummit, and for reminding us why our work matters. 

I just returned from CytoSummit in Crete. Together with the CytoReason team and an impressive group of industry experts, we focused on one question: "How can we empower our customers to improve the probability of success in phase 2 clinical trials?" Low efficacy remains one of the biggest challenges in drug development today. 90% of drug candidates fail in clinical trials, resulting in hundreds of millions of dollars and years of research being lost. At CytoReason, we use our proprietary disease models to tackle this challenge. We help our customers identify the right indications and the most responsive patients—before trials even begin. While outcomes can never be fully assured, our goal is to provide data-driven insights that give scientists and pharma executives the confidence to make informed decisions and maximize their chances of success. Learn more about our disease models via the link in the comment below 👇

Fascinating episode of Tech on Drugs is up today with AION Labs CTO Yair Benita. Among the highlights: •⁠ ⁠What major shift did Keytruda's development introduce to the industry? •⁠ ⁠How did pharma's 'Kodak moment’ come about? •⁠ ⁠What needs to happen in pharma R&D so data is no longer JUST supporting decisions, but actually driving them? Yair is an accomplished computational biologist who spent more than 20 years studying biology through omics and clinical data in an effort to piece together mechanisms of human disease. He’s been leading computational teams in drug discovery at CytoReason, Compugen, and Merck. In this candid conversation, Yair reflects with me on the highs and the lows of the past two decades - in his professional journey, and in the industry at large. Link to full episode in comment below 👇

שנה קשוחה עברה על כולנו, גם על מנהלות HR. אבל כדברי צ׳רצ׳יל: "לעולם אל תיתן למשבר טוב להתבזבז". מאמר מלא תובנות בהשתתפות VP HR של סייטוריזן - Michal Katzir. למאמר המלא: https://lnkd.in/ejS8THhy

It’s been a tough year in Israel and in the world.   Our work at CytoReason keeps us sane (mostly), our connections keep us happy, our mission - to improve probability of success in clinical trials – brings us meaning.   Wishing a Happy Rosh Hashanah to all those celebrating! 🍯🍎 שנה טובה🍷🍏

At CytoSummit, on the beautiful island of Crete, we gathered CytoReason’s employees to tackle one of the biggest challenges facing drug developers today: improving the probability of success in Phase 2 clinical trials. With an incredible lineup of guest speakers, we explored the latest advances in generative AI for drug development and reflected on CytoReason’s differentiated position in the digital health market. David Ruau - NVIDIA, Marie Lübkert - Nomura, Dr Leonid Shapiro - Candesic, Yair Benita - AION Labs, Parker Moss - Exscientia

We just came back from CytoSummit, our annual employee conference, held on the beautiful island of Crete. CytoSummit is first and foremost about honoring our people. It’s been a challenging year, and without the passion, hard work, and great minds of our amazing Cytos, there's no way we would have powered through. We faced some tough questions throughout our stay. Souvlaki or Gyros? Ouzo or Tsipouro? Beach strolls or mountain hikes? But in all seriousness, we focused on the question we’ve asked from day one at CytoReason: "How can we improve the probability of success in phase 2 clinical trials?" We believe that tackling this challenge with our differentiated computational models will not only help our customers make medicine more predictable, but more importantly, improve the lives of people battling some of the most debilitating diseases out there. A big thank you to our guests, including Parker Moss from Exscientia, David Ruau from NVIDIA, Yair Benita from AION Labs, Dr Leonid Shapiro from Candesic, and Marie Lübkert from Nomura. Your insights helped us zoom out beyond our day-to-day work, and remember that we’re at the forefront of pharma AI. We came back feeling proud. Stay tuned for more takeaways from CytoSummit in the coming weeks!

Two years ago we launched the "Make Mom Proud" campaign on LinkedIn AND on Azrieli's digital billboard. We found some great people - among them rockstar bioinformaticians that deeply care about making a positive impact on human health. We're still on the lookout for those exceptional bioinformaticians looking to do meaningful work with multi-disciplinary teams, immerse themselves in cutting edge science, while helping our customers write the next chapter in the biopharma industry. If, like Lior Faigon here, you're one of those people, please see the job description and apply here: https://lnkd.in/d9DabKa2 PS. stay tuned for our next employer branding campaign. It's exciting 🎉

Congratulations Poolbeg Pharma plc on this prestigious accomplishment. It was a privilege working with you on this important project.

We're hiring a Backend Tech Leader! Come work with a team of rockstar scientists, programmers, engineers, and with some of the biggest players in pharma (Pfizer), life sciences (Thermo Fisher), AI (NVIDIA). You'll help us build more and better computational models to simulate disease biology and predict treatment effects. It's hard work, but it's meaningful and fun! Apply here: https://lnkd.in/dBgC3DVR